{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:47:48Z","timestamp":1787021268238,"version":"build-2736575974"},"reference-count":61,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFA0109800"],"award-info":[{"award-number":["2018YFA0109800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070585"],"award-info":[{"award-number":["82070585"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Research and Development Program of Zhejiang Province","award":["2020C03033"],"award-info":[{"award-number":["2020C03033"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Elevated serum remnant cholesterol independently predicts risks of cardiovascular diseases. However, the association between remnant cholesterol and metabolic dysfunction\u2013associated fatty liver disease (MAFLD) remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to explore the association of remnant cholesterol with MAFLD and its long-term mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We extracted data from the NHANES III, 1988 to1994 and the linked mortality data until December 31, 2015. The association between remnant cholesterol and MAFLD was analyzed by multivariable logistic regression. Cox proportional hazards regression was performed to assess whether elevated remnant cholesterol increased all-cause and cause-specific mortalities in MAFLD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, 28.6% (1474\/5156) of participants had MAFLD. In multivariable logistic regression, the fourth quartile of remnant cholesterol was associated with an increased risk of MAFLD compared with the first quartile (odds ratio [OR]: 1.714; 95% CI, 1.586-1.971; P\u2005&amp;lt;\u2005.001). In participants with normal levels of triglycerides, low-density lipoprotein and high-density lipoprotein cholesterol, the relationship between remnant cholesterol and MAFLD risk remained significant (OR: 1.346; 95% CI, 1.248-1.761; P\u2005&amp;lt;\u2005.001). During a median follow-up of 307 months, MAFLD patients with serum remnant cholesterol in the fourth quartile were associated with a higher risk of all-cause mortality (hazard ratio [HR]: 2.183; 95% CI, 1.825-2.407; P\u2005&amp;lt;\u2005.001), as well as a higher risk of cardiovascular mortality (HR: 2.346; 95% CI, 2.046-2.885; P\u2005&amp;lt;\u2005.001) and cancer-related mortality (HR: 2.366; 95% CI, 1.864-2.932; P\u2005&amp;lt;\u2005.001) compared with MAFLD patients in the first quartile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Remnant cholesterol was independently associated with the risk of MAFLD and predicted all-cause, cardiovascular, and cancer-related mortalities in MAFLD patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgac283","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T07:37:19Z","timestamp":1651822639000},"page":"e3295-e3303","source":"Crossref","is-referenced-by-count":59,"title":["Remnant Cholesterol Predicts Long-term Mortality of Patients With Metabolic Dysfunction\u2013associated Fatty Liver Disease"],"prefix":"10.1210","volume":"107","author":[{"given":"Hangkai","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine , Hangzhou 310003 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine , Hangzhou 310003 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhening","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine , Hangzhou 310003 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine , Hangzhou 310003 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine , Hangzhou 310003 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6172-1253","authenticated-orcid":false,"given":"Chengfu","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine , Hangzhou 310003 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"issue":"6","key":"2022071417211113400_CIT0001","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology."},{"issue":"7","key":"2022071417211113400_CIT0002","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology."},{"issue":"9","key":"2022071417211113400_CIT0003","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut."},{"issue":"3","key":"2022071417211113400_CIT0004","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J Hepatol."},{"issue":"6","key":"2022071417211113400_CIT0005","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/hep.28123","article-title":"Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009","volume":"62","author":"Younossi","year":"2015","journal-title":"Hepatology."},{"issue":"1","key":"2022071417211113400_CIT0006","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol."},{"issue":"2","key":"2022071417211113400_CIT0007","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jhep.2021.05.003","article-title":"The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease","volume":"75","author":"Nan","year":"2021","journal-title":"J Hepatol."},{"issue":"19","key":"2022071417211113400_CIT0008","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1097\/CM9.0000000000000981","article-title":"From NAFLD to MAFLD: a \u201credefining\u201d moment for fatty liver disease","volume":"133","author":"Zheng","year":"2020","journal-title":"Chin Med J (Engl)."},{"issue":"2","key":"2022071417211113400_CIT0009","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pathol.2018.11.006","article-title":"Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment","volume":"51","author":"Carr","year":"2019","journal-title":"Pathology."},{"issue":"7","key":"2022071417211113400_CIT0010","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2337\/db16-0046","article-title":"Pharmacological targeting of the atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond lowering LDL cholesterol","volume":"65","author":"Xiao","year":"2016","journal-title":"Diabetes."},{"key":"2022071417211113400_CIT0011","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1475-2840-5-20","article-title":"Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins","volume":"5","author":"Tenenbaum","year":"2006","journal-title":"Cardiovasc Diabetol."},{"issue":"1","key":"2022071417211113400_CIT0012","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J."},{"issue":"39","key":"2022071417211113400_CIT0013","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J."},{"issue":"11","key":"2022071417211113400_CIT0014","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur Heart J."},{"key":"2022071417211113400_CIT0015","doi-asserted-by":"crossref","first-page":"1K","DOI":"10.1016\/j.amjcard.2008.10.002","article-title":"The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia","volume":"102","author":"Fruchart","year":"2008","journal-title":"Am J Cardiol."},{"issue":"23","key":"2022071417211113400_CIT0016","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.jacc.2020.10.008","article-title":"Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease","volume":"76","author":"Casta\u00f1er","year":"2020","journal-title":"J Am Coll Cardiol."},{"issue":"10","key":"2022071417211113400_CIT0017","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/2047487319887578","article-title":"Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease","volume":"27","author":"Elshazly","year":"2020","journal-title":"Eur J Prev Cardiol."},{"issue":"6","key":"2022071417211113400_CIT0018","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jacl.2015.08.009","article-title":"Premature myocardial infarction is strongly associated with increased levels of remnant cholesterol","volume":"9","author":"Goliasch","year":"2015","journal-title":"J Clin Lipidol."},{"issue":"2","key":"2022071417211113400_CIT0019","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1210\/er.2018-00184","article-title":"The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk","volume":"40","author":"Sandesara","year":"2019","journal-title":"Endocr Rev."},{"issue":"3","key":"2022071417211113400_CIT0020","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.pharmthera.2013.11.008","article-title":"Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment","volume":"141","author":"Varbo","year":"2014","journal-title":"Pharmacol Ther."},{"issue":"4","key":"2022071417211113400_CIT0021","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"2022071417211113400_CIT0022","article-title":"Supplementary data for \u201cRemnant cholesterol predicts long-term mortality of patients with metabolic dysfunction-associated fatty liver disease.\u201d","author":"Huang","year":"2022"},{"issue":"9","key":"2022071417211113400_CIT0023","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.14309\/ajg.0000000000000654","article-title":"Low thyroid function in nonalcoholic fatty liver disease is an independent predictor of all-cause and cardiovascular mortality","volume":"115","author":"Kim","year":"2020","journal-title":"Am J Gastroenterol."},{"issue":"16","key":"2022071417211113400_CIT0024","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation."},{"key":"2022071417211113400_CIT0025","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2337\/dc20-S002","article-title":"2. Classification and diagnosis of diabetes; Standards of Medical Care in Diabetes\u20142020","volume":"43","author":"American Diabetes Association","year":"2020","journal-title":"Diabetes Care."},{"issue":"23","key":"2022071417211113400_CIT0026","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1016\/j.jacc.2019.03.507","article-title":"ACC\/AHA versus ESC\/ESH on hypertension guidelines: JACC guideline comparison","volume":"73","author":"Bakris","year":"2019","journal-title":"J Am Coll Cardiol."},{"issue":"11","key":"2022071417211113400_CIT0027","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.numecd.2020.07.002","article-title":"Remnant cholesterol as a risk factor for cardiovascular, cancer or other causes mortality: a competing risks analysis","volume":"30","author":"Bonfiglio","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis."},{"issue":"1","key":"2022071417211113400_CIT0028","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12933-020-01076-7","article-title":"The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes","volume":"19","author":"Cao","year":"2020","journal-title":"Cardiovasc Diabetol."},{"issue":"4","key":"2022071417211113400_CIT0029","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1373\/clinchem.2015.253757","article-title":"Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease","volume":"62","author":"Jepsen","year":"2016","journal-title":"Clin Chem."},{"issue":"6","key":"2022071417211113400_CIT0030","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1530\/EC-19-0116","article-title":"Serum retinol-binding protein 4 levels in polycystic ovary syndrome","volume":"8","author":"Lingaiah","year":"2019","journal-title":"Endocr Connect."},{"issue":"8","key":"2022071417211113400_CIT0031","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/CIRCULATIONAHA.117.032318","article-title":"Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial","volume":"138","author":"Vallejo-Vaz","year":"2018","journal-title":"Circulation."},{"issue":"9","key":"2022071417211113400_CIT0032","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/0003319719854296","article-title":"Remnant lipoprotein cholesterol independently associates with in-stent restenosis after drug-eluting stenting for coronary artery disease","volume":"70","author":"Xu","year":"2019","journal-title":"Angiology."},{"issue":"12","key":"2022071417211113400_CIT0033","first-page":"3546","article-title":"Remnant cholesterol and cardiovascular mortality in patients with type 2 diabetes and incident diabetic nephropathy","volume":"106","author":"Yu","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022071417211113400_CIT0034","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jjcc.2016.12.010","article-title":"Remnant cholesterol predicts periprocedural myocardial injury following percutaneous coronary intervention in poorly-controlled type 2 diabetes","volume":"70","author":"Zeng","year":"2017","journal-title":"J Cardiol."},{"issue":"17","key":"2022071417211113400_CIT0035","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation."},{"issue":"42","key":"2022071417211113400_CIT0036","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1093\/eurheartj\/ehab432","article-title":"Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study","volume":"42","author":"Quispe","year":"2021","journal-title":"Eur Heart J."},{"issue":"4","key":"2022071417211113400_CIT0037","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2337\/dbi19-0007","article-title":"Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease","volume":"69","author":"Chait","year":"2020","journal-title":"Diabetes."},{"issue":"1","key":"2022071417211113400_CIT0038","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/clinchem\/hvaa296","article-title":"Triglyceride-rich lipoprotein remnants and cardiovascular disease","volume":"67","author":"Duran","year":"2021","journal-title":"Clin Chem."},{"issue":"4","key":"2022071417211113400_CIT0039","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res."},{"issue":"23","key":"2022071417211113400_CIT0040","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1016\/j.jacc.2020.10.029","article-title":"Remnant cholesterol and atherosclerotic cardiovascular disease risk","volume":"76","author":"Burnett","year":"2020","journal-title":"J Am Coll Cardiol."},{"issue":"12","key":"2022071417211113400_CIT0041","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s00592-021-01765-z","article-title":"Association of remnant cholesterol with chronic kidney disease in middle-aged and elderly Chinese: a population-based study","volume":"58","author":"Yan","year":"2021","journal-title":"Acta Diabetol."},{"issue":"2","key":"2022071417211113400_CIT0042","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1\u2014full report","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol."},{"issue":"1","key":"2022071417211113400_CIT0043","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12933-016-0454-x","article-title":"Cholesterol remnants and triglycerides are associated with decreased myocardial function in patients with type 2 diabetes","volume":"15","author":"J\u00f8rgensen","year":"2016","journal-title":"Cardiovasc Diabetol."},{"key":"2022071417211113400_CIT0044","doi-asserted-by":"crossref","first-page":"693507","DOI":"10.3389\/fmed.2021.693507","article-title":"NAFLD or MAFLD: which has closer association with all-cause and cause-specific mortality? Results from NHANES III","volume":"8","author":"Huang","year":"2021","journal-title":"Front Med (Lausanne)."},{"issue":"10","key":"2022071417211113400_CIT0045","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.cgh.2021.05.029","article-title":"Differential clinical characteristics and mortality outcomes in persons with NAFLD and\/or MAFLD","volume":"19","author":"Nguyen","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"2022071417211113400_CIT0046","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.jhep.2021.07.035","article-title":"Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States","volume":"75","author":"Kim","year":"2021","journal-title":"J Hepatol."},{"key":"2022071417211113400_CIT0047","doi-asserted-by":"crossref","first-page":"101238","DOI":"10.1016\/j.molmet.2021.101238","article-title":"Metabolic-associated fatty liver disease and lipoprotein metabolism","volume":"50","author":"Heeren","year":"2021","journal-title":"Mol Metab."},{"issue":"1","key":"2022071417211113400_CIT0048","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12944-021-01573-y","article-title":"Association of remnant cholesterol with nonalcoholic fatty liver disease: a general population-based study","volume":"20","author":"Zou","year":"2021","journal-title":"Lipids Health Dis."},{"issue":"10","key":"2022071417211113400_CIT0049","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","article-title":"Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study","volume":"19","author":"Lee","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"2022071417211113400_CIT0050","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1210\/clinem\/dgab641","article-title":"Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China","volume":"107","author":"Liang","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2022071417211113400_CIT0051","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/hep.30864","article-title":"Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts","volume":"71","author":"\u00c5berg","year":"2020","journal-title":"Hepatology."},{"issue":"10","key":"2022071417211113400_CIT0052","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.cgh.2017.04.045","article-title":"Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity","volume":"15","author":"Fracanzani","year":"2017","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"12","key":"2022071417211113400_CIT0053","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1038\/ng.3977","article-title":"Exome-wide association study of plasma lipids in &gt;\u2005300,000 individuals","volume":"49","author":"Liu","year":"2017","journal-title":"Nat Genet"},{"key":"2022071417211113400_CIT0054","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cca.2014.10.029","article-title":"The role of circulating lipoprotein lipase and adiponectin on the particle size of remnant lipoproteins in patients with diabetes mellitus and metabolic syndrome","volume":"440","author":"Shirakawa","year":"2015","journal-title":"Clin Chim Acta."},{"issue":"21-22","key":"2022071417211113400_CIT0055","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.cca.2010.07.004","article-title":"Delayed postprandial metabolism of triglyceride-rich lipoproteins in obese young men compared to lean young men","volume":"411","author":"Nabeno-Kaeriyama","year":"2010","journal-title":"Clin Chim Acta."},{"issue":"23","key":"2022071417211113400_CIT0056","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/j.jacc.2014.09.042","article-title":"Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease","volume":"64","author":"Rosenson","year":"2014","journal-title":"J Am Coll Cardiol."},{"issue":"2","key":"2022071417211113400_CIT0057","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.metabol.2003.08.016","article-title":"Lipoprotein lipase activator NO-1886 improves fatty liver caused by high-fat feeding in streptozotocin-induced diabetic rats","volume":"53","author":"Kusunoki","year":"2004","journal-title":"Metabolism."},{"issue":"1","key":"2022071417211113400_CIT0058","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bbrc.2007.02.129","article-title":"Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis","volume":"356","author":"Yu","year":"2007","journal-title":"Biochem Biophys Res Commun."},{"key":"2022071417211113400_CIT0059","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12944-017-0410-0","article-title":"Predictive value of non-fasting remnant cholesterol for short-term outcome of diabetics with new-onset stable coronary artery disease","volume":"16","author":"Hong","year":"2017","journal-title":"Lipids Health Dis."},{"issue":"12","key":"2022071417211113400_CIT0060","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","article-title":"Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation","volume":"128","author":"Varbo","year":"2013","journal-title":"Circulation."},{"issue":"38","key":"2022071417211113400_CIT0061","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.3748\/wjg.v16.i38.4773","article-title":"Hepatic steatosis, low-grade chronic inflammation and hormone\/growth factor\/adipokine imbalance","volume":"16","author":"Tarantino","year":"2010","journal-title":"World J Gastroenterol."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac283\/43741698\/dgac283.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/8\/e3295\/44886399\/dgac283.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/8\/e3295\/44886399\/dgac283.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T13:22:17Z","timestamp":1657804937000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/8\/e3295\/6581631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,6]]},"references-count":61,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,5,6]]},"published-print":{"date-parts":[[2022,7,14]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac283","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,5,6]]}}}